← Hansoh Pharmaceutical Group Co Limited/ADR (HNSPF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Hansoh Pharmaceutical Group Co Limited/ADR (HNSPF)
Biotechnology · market cap $25.8B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-03-07 (est.)
Phase 3
Pipeline
15
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Hansoh Pharmaceutical Group (HNSPF) is a China-based biotechnology company with approximately 9,313 employees and a market capitalization of roughly $23.2 billion. The company operates a broad pipeline spanning oncology, metabolic disease, immunology, and infectious disease, with multiple assets in Phase 2 and Phase 3 trials. The nearest binary catalysts are a Phase 2 readout for lead oncology asset HS-20093 expected around July 31, 2026, and a Phase 3 Topotecan readout in small cell lung cancer expected around September 30, 2026.
The catalyst path
- 2027-03-07 (est.)Phase 3 · HS-20089imp 9/10
- 2027-07-10 (est.)Phase 2 · HS-10516 + Lenvatinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| HS-20093 | Phase 3 | Advanced Solid Tumor |
| PEG-Tα1 | Phase 2 | Hepatitis B, Chronic |
| Aumolertinib | Phase 3 | Non-small Cell Lung Cancer |
| HS-20094 5mg | Phase 2 | Type 2 Diabetes |
| HS-20089 | Phase 3 | Ovarian Cancer |
| HS-10374 | Phase 2 | Psoriatic Arthritis |
| HS-10516 + Lenvatinib | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma |
| HS-10370 | Phase 2 | Advanced Solid Tumor |
| Flumatinib 600mg qd | Phase 3 | CML, CML-CP,MMR,TKI |
| Almonertinib | Phase 3 | Non-small Cell Lung Cancer |
| HS-20117 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer |
| HS-10234 | Phase 3 | Chronic HBV Infection |
| HS-20094 injection | Phase 3 | Overweight |
| iloperidone | Phase 2 | Schizophrenia |
| Pegol-Sihematide | Phase 3 | Chronic Kidney Diseases |
Price & technical context
3-month
+11.0%
6-month
-17.6%
12-month
-5.6%
52-wk range
$3.83–$5.16
vs 50-day MA
+0.8%
vs 200-day MA
-6.2%
Realized vol
32.3%
Max drawdown
-56.7%
Daily closes through 2026-09-29. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HNSPF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.